BORTEZOMIB

SynDRA canonical compound SYN0004189 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	PSMB5
Mechanism of action	NFKB pathway inhibitor
Indication	mantle cell lymphoma (MCL) \| multiple myeloma
Disease area	hematologic malignancy

All known targets

LDP-341
PS-341
velcade
radiciol
Bortezomib hydrate
NSC-681239
Velcade
Bortezomib (PS-341)
UNII-69G8BD63PP
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
MLN-341
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
CHEMBL325041
69G8BD63PP
Boronic acid,
DPBA
PROSCRIPT BORONIC ACID
LPD-341
VELCADE (TN)
Pyz-Phe-boroLeu
Bortezomib(JAN/USAN/INN)
Velcade, MG-341, PS-341, Bortezomib
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
Bortezomib (Proteasome inhibitor)
Peptide boronate
Ps 341
LDP 341
((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid
Bortezomib accord
NSC 681239
Bortezomib (Velcade)
MG-341
Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
CHEBI:52717
NSC681239
NCGC00242506-02
S1013